Attendee search 

PxRadia is applying its HD-mAb technology platform to provide increased therapeutic potency to biosimiliar monoclonal antibodies. These antibodies are directed to validated targets such as Her-2, CD-20 and PD-1/PD-L.  We and our partners will share new IP and rights and differentiation from current products in the marketplace.

IMS Health Capital (IMSHC) is a niche life-science focused investment bank which manages financing transactions, and advises on M&A and licensing/partnering transactions.

IMS Health Capital (IMSHC) is a fully owned subsidiary of IMS Health, Inc. (www.imshealth.com) and affiliated with IMS Consulting Group (www.imscg.com).

IMSHC has privileged access to a vast array of IMS Health’s resources and connections and can help prepare a compelling value proposition and put you in touch with the right interested parties.  Our team has extensive life-science industry experience and can provide support at any and all stages of the transaction process.  Unlike most investment banks or business development consultants, IMSHC has immense strategic partnering capabilities and can work with companies on both partnering and financing efforts.  Given our unique positioning and access to a vast array of information and relationships, we see a high volume of opportunities.

IMSHC is a SEC/FINRA licensed broker dealer and a wholly owned subsidiary of IMS Health, Inc.  IMS Health Inc. is publicly traded on the NYSE under the ticker “IMS”, and is the world’s leading information, services and technology company in the Life Sciences sector.  Customers of IMS Health’s data and consulting services include most of the top names in pharmaceutical, medical device and consumer health manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community (www.imshealth.com).

MyeloRx is a northern California based biotechnology company. Our lead compound, MRx102, is a small molecule inhibitor of RNA polymerase II. Molecules related to MRx102 have shown clinical efficacy in AML patients in Europe and China.  MRx102 is covered by issued composition of matter patents in the U.S., E.U., China and Japan.  While AML is the initial indication, MRx102 has also been found active in stringent models of pancreatic and lung cancer. Our collaborators include clinical oncologists from MD Anderson Cancer Center, JHU School of Medicine and City of Hope Medical Center. R&D activities have been funded primarily by a $2M NCI SBIR contract. Our strong scientific and management team is lead by Dr. John Musser; it has brought multiple products to market. We are seeking funding to complete an IND which is projected to take less than a year based on the extensive studies completed to date (manufacturing, formulation, toxicology/ PK in rats and dogs etc.)  and a Phase 1 clinical trial in AML patients.